 Stenosis
(EVA-3S)7 and Stent Protected Angioplasty vs CEA
(SPACE1),8 examined CAS vs CEA in neurologically
symptomatic patients. EVA-3S showed a statistically
inferior 30-day outcome for transfemoral CAS compared
with CEA (stroke death, 9.5% vs 3.8%) in these patients.
However, this study was criticized because of the relatively low level